



**CHINA MEDICAL (INTERNATIONAL)
GROUP LIMITED**

中国医疗(国际)集团有限公司

MEDIA RELEASE

CHINA MEDICAL SIGNS DEAL TO ACQUIRE 51% STAKE IN COMPANIES BEHIND THE SLOANE CLINIC

- *The Sloane Clinic will expand China Medical's aesthetics medical business geographically and deepen its expertise and service offerings*
- *China Medical to hold EGM for shareholder approval*
- *\$9.5 million cash and share deal aims to complete on 31 Dec 2016*

Singapore, 8 November 2016 – China Medical (International) Group Limited today announced that it has entered into a share purchase agreement for the acquisition of 51% of two companies that collectively own and operate the established aesthetics medical network, The Sloane Clinic.

The share purchase agreement signed today is for 51% of the issued share capital of Eastlife Pte Ltd and Maxglobe Pte. Ltd., which own clinics operating under The Sloane Clinic brand in Singapore and Malaysia. The seller, Asia Pacific Medical Group Limited, is a medical group that provides a range of primary care and specialty services.

China Medical announced the Framework Agreement on 21 October 2016. The \$9.5 million acquisition comprises \$6.5 million in cash and \$3.0 million of 238,095,238 China Medical shares at 1.26 cents a share. The share price represents a 10% discount from the volume-weighted average share price for the full trading day before the share purchase agreement was executed.

China Medical will, for good corporate governance reasons, hold an Extraordinary General Meeting for shareholders to approve the transaction



**CHINA MEDICAL (INTERNATIONAL)
GROUP LIMITED**

中国医疗(国际)集团有限公司

notwithstanding the fact that the acquisition does not constitute a major transaction that requires shareholders' prior approval.

The deal marks the first acquisition for China Medical, after it was renamed from Albedo Limited in April 2016 following a revamp of its business strategy from metal trading to medical aesthetics in late 2015. It will give the group a major presence in the Singapore and Malaysia aesthetics market.

China Medical will also enter into exclusive a new service agreement with The Sloane Clinic's lead doctor, Dr Kenneth Lee, and employment agreements with his group of doctors. Dr Lee will continue to operate and manage the aesthetic and plastic surgery group, and his group of doctors will be employed full-time and will be required to commit their skills and resources exclusively to The Sloane Clinic for an initial period of five years.

A performance assurance guaranteeing net profit after tax of not less than \$6.0 million for the next three financial years from 2017 to 2019 will also be given. In consideration of the performance assurance, China Medical will issue \$2.0 million worth of shares on completion of the acquisition to him and/or his group of doctors.

The Sloane Clinic provides aesthetic medical services including botox, laser treatments, dermal fillers, liposuction, cellulite reductions, breast augmentations, plastic surgery and anti-ageing treatments.

- The End -



**CHINA MEDICAL (INTERNATIONAL)
GROUP LIMITED**

中国医疗(国际)集团有限公司

About China Medical (International) Group Limited

China Medical (International) Group Limited is formerly known as Albedo Limited, which was founded by Chairman Tai Kok Chuan in 1988. Albedo was involved in the trading of semi-finished and finished products to the iron and steel industry in the Asia Pacific region, and was listed on the then SGX-SESDAQ in 2006. In 2015, Albedo acquired a 51% stake in China iMyth Company Pte. Ltd., which is involved in a range of medical aesthetics and healthcare services including botox, laser treatments, dermal fillers, liposuctions, cellulite reductions, breast augmentations, plastic surgery, anti-ageing treatments and detoxification.

For media queries, please contact: Catherine Ong Associates Pte Ltd

Catherine Ong
Tel: +65 6327 6088
Cell: +65 9697 0007
Email: cath@catherineong.com

Farhan Zohri
Tel: +65 6327 6089
Cell: +65 8318 9665
Email: farhan@catherineong.com

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.